Imidazoline derivatives: A patent review (2006 present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 11, 2012, Pages 1353-1365

  Guan, Xianghong ^a   Hu, Yongzhou ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

G protein coupled receptor; Imidazoline; Inhibitors of enzyme; Nuclear factor kappa B inhibitors; P53MDM2

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA SECRETASE; BETA SECRETASE INHIBITOR; CAMPTOTHECIN; CARBAPENEM DERIVATIVE; CHEMOKINE RECEPTOR CCR1; CITALOPRAM; COMBRETASTATIN A4; DICARBOXYLIC ACID DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOXORUBICIN; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HYDANTOIN DERIVATIVE; I KAPPA B; IDAZOXAN; IMIDAZOLINE DERIVATIVE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NUTLIN 3; PHENTOLAMINE; PROTEIN MDM2; PROTEIN P53; SEROTONIN UPTAKE INHIBITOR; SITAGLIPTIN; TOLAZOLINE;

ADDICTION; ALLERGY; ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; APOPTOSIS; ASTHMA; ATHEROSCLEROSIS; BINDING AFFINITY; BLADDER DISEASE; CARDIOVASCULAR DISEASE; CROHN DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GLUCOSE HOMEOSTASIS; HUMAN; HYPOTENSION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MENINGITIS; MYDRIASIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTITIS; PAIN; PATENT; PRESYNAPTIC INHIBITION; PROTEIN PROTEIN INTERACTION; PRURITUS; PSORIASIS; RESPIRATION DEPRESSION; REVIEW; SEPSIS; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; ULCERATIVE COLITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; IMIDAZOLINES; MOLECULAR STRUCTURE; NF-KAPPA B; PATENTS AS TOPIC; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867808741     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.727397     Document Type: Review

References (96)

1. Szabo B. Imidazoline antihypertensive drugs: A critical review on their mechanism of action. Pharmacol Therapeut 2002;93(1):1-35
2. Jin J, Kittanakom S, Wong V, et al. Interaction of the mu-opioid receptor with GPR177 (Wntless) inhibits Wnt secretion: Potential implications for opioid dependence. BMC Neurosci 2010;11:33
3. Oertel BG, Schmidt R, Schneider A, et al. The mu-opioid receptor gene polymorphism 118A > G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genom 2006;16(9):625-36
4. Goodman AJ, Le Bourdonnec B, Dolle RE. Mu opioid receptor antagonists: Recent developments. Chem Med Chem 2007;2(11):1552-70
5. Pasternak G, Pan YX. Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan 2011; 49(1):21-5
6. Ray LA, Barr CS, Blendy JA, et al. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: A critical review. Alcohol Clin Exp Res 2012;36(3):385-94
7. Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol 2010;63(4):680-8
8. Ingram SL, Traynor Jr. Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: From pharmacological curiosity to therapeutic potential. Brit J Pharmacol 2009;158(1):154-6
9. Merla B, Oberboersch S, Sundermann B, et al. Substituted imidazoline derivatives. WO2007079927; 2007
10. Galley G, Groebke Zbinden K, Norcross R, et al. 2-imidazolines having a good affinity to the trace amine associated receptors (TAARs). WO2009003868; 2009
11. Miller GM. Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1). J Med Chem 2012;55(5):1809-14
12. Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 2011;116(2):164-76
13. Sotnikova TD, Zorina OI, Ghisi V, et al. Trace amine associated receptor 1 and movement control. Parkinsonism Relat D 2008;14(Suppl 2):S99-102
14. Borowsky B, Adham N, Jones KA, et al. Trace amines: Identification of a family of mammalian G protein-coupled receptors. P Natl Acad Sci USA 2001;98(16):8966-71
15. Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4- methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001;60(6):1181-8
16. Horie K, Obika K, Foglar R, et al. Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha(1)-adrenoceptor subtypes. Brit J Pharmacol 1995;116(1):1611-18
17. Jain KS, Bariwal JB, Kathiravan MK, et al. Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents. Bioorgan Med Chem 2008; 16(9):4759-800
18. Sorbera LA, Castaner J. Dabuzalgron hydrochloride. Treatment of urinary incontinence, alpha(1A/1L)-Adrenoceptor partial agonist. Drug Future 2004;29(3):216-19
19. Muramatsu I, Kitagawa H. Imidazoline derivative. WO2009128479; 2009
20. Takahashi T, Kanakubo N, Kobayashi T, et al. Imidazoline derivatives. WO2012008565; 2012
21. Ford A, Williams TJ, Blue DR, et al. Alpha-1-adrenoceptor classification - sharpening occam's razor. Trends Pharmacol Sci 1994;15(6):167-70
22. Chern JW, Tao PL, Yen MH, et al. Studies on quinazolines. 5. 2,3-dihydroimidazo 1,2-c quinazoline derivatives - a novel class of potent and selective alpha(1)-adrenoceptor antagonists and antihypertensive agents. J Med Chem 1993;36(15):2196-207
23. Horn G. Method and composition which reduces stimulation of muscles which dilate the eye. US2006211753; 2006
24. Garst ME, Dolby LJ, Esfandiari S, et al. Method of making imidazole-2-thiones. WO2006062890; 2006
25. Devita VT, Schein PS. The use of drugs in combination for the treatment of cancer: Rationale and results. N Engl J Med 1973;288(19):998-1006
26. Maes M, Meltzer HY. The serotonin hypothesis of major depression. Raven Press; New York: 1995
27. Maes M, Van Gastel A, Delmeire L, et al. Decreased platelet alpha-2 adrenoceptor density in major depression: Effects of tricyclic antidepressants and fluoxetine. Biol Psychiat 1999; 45(3):278-84
28. Costagliola C, Parmeggiani F, Semeraro F, et al. Selective serotonin reuptake inhibitors: A Review of its effects on intraocular pressure. Curr Neuropharmacol 2008;6(4):293-310
29. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed-patients treated with serotonin reuptake inhibitors. Arch Gen Psychiat 1994;51(3):248-51
30. Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebocontrolled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349(9065):1594-7
31. Svensson T, Langger S, Langer SZ. Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor. WO2006083204; 2006
32. Zhang P, Pennell AMK, Li L, et al. Oxo-imidazolidines as modulators of chemokine receptors. US2008269280; 2008
33. Haga Y, Moriya M, Takahashi T. 2. Aryl imidazoline derivatives. WO2010123150; 2010
34. Mendieta L, Tarrago T, Giralt E. Recent patents of dipeptidyl peptidase IV inhibitors. Expert Opin Ther Pat 2011;21(11):1693-741
35. Yang B CN, Hu Y CN, He Q CN, et al. New imidazoline-2,4-diketone derivative as dipeptidyl peptidase IV inhibitor used for preventing type II diabetes or regulating blood sugar level. CN101875636; 2010
36. Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Deliver Rev 2002;54(12):1539-51
37. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001;32(2):177-80
38. Hardy J, Duff K, Hardy KG, et al. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat Neurosci 1998;1(5):355-8
39. Roses AD. Alzheimer diseases: A model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am J Med Genet 1998; 81(1):49-57
40. Ray WJ, Yao M, Mumm J, et al. Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J Biol Chem 1999;274(51): 36801-7
41. Ghosh AK, Brindisi M, Tang J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 2012;120(Suppl 1):71-83
42. Arbel M, Solomon B. A novel immunotherapy for Alzheimer's disease: Antibodies against the beta-secretase cleavage site of APP. Curr Alzheimer Res 2007;4(4):437-45
43. Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Deliv Rev 2002;54(12):1589-602
44. Berg S, Hoegdin K, Kihlstroem J, et al. Amino-imidazolines and their use as a medicament for treating cognitive impairment, Alzheimer disease, neurodegeneration and dementia. WO2007145568; 2007
45. Zhou P, Bernotas RC, Li Y, et al. 2- Amino-5-piperidinylimidazolone compounds and use thereof for (insert beta symbol)-secretase modulation. WO2007078813; 2007
46. Quagliato DA, Andrae PM, Fan Y. Dihydrospiro[dibenzo[a,d][7]annulene- 5,4'-imidazol] compounds for the inhibition of beta-secretase. US2007203116; 2007
47. Berg S, Burrows J, Chessari G, et al. Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. WO2007058602; 2007
48. Albert J, Arnold J, Chessari G, et al. Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. WO2007058601; 2007
49. Lane DP, Crawford LV. T-antigen is bound to a host protein in sv40-transformed cell. Nature 1979; 278(5701):261-3
50. Linzer DIH, Levine AJ. Characterization of a 54k Dalton cellular sv40 tumor-antigen present in sv40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17(1):43-52
51. Khoury K, Popowicz GM, Holak TA, et al. The p53-MDM2/MDMX axis - A chemotype perspective. Medchemcomm 2011;2(4):246-60
52. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002;2(8):594-604
53. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69(7):1237-45
54. Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature 1997;387(6630):296-9
55. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. Febs Lett 1997;420(1):25-7
56. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387(6630):299-303
57. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein mdm2 conceals the activation domain of tumor suppressor-p53. Nature 1993; 362(6423):857-60
58. Tao WK, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. P Natl Acad Sci USA 1999;96(6):3077-80
59. Millard M, Pathania D, Grande F, et al. Small-molecule inhibitors of p53-MDM2 interaction: The 2006-2010 update. Curr Pharm Design 2011;17(6):536-59
60. Dickens MP, Fitzgerald R, Fischer PM. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 2010;20(1):10-18
61. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
62. Fotouhi N, Haley GJ, Simonsen KB, et al. Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments. WO2006097261-A1; 2006
63. Fotouhi N, Haley GJ, Simonsen KB, et al. Chiral cis-imidazolines. US2009143364; 2009
64. Ding Q, Graves BJ, Kong N, et al. 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents. WO2007063013; 2007
65. Bartkovitz DJ, Cai J, Chu X, et al. Chiral cis-imidazolines. WO2009047161; 2009
66. Patton JT, Mayo LD, Singhi AD, et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3. Cancer Res 2006;66(6):3169-76
67. Wade M, Wong ET, Tang M, et al. Hdmx modulates the outcome of P53 activation in human tumor cells. J Biol Chem 2006;281(44):33036-44
68. Hu B, Gilkes DM, Farooqi B, et al. MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin. J Biol Chem 2006;281(44):33030-5
69. Xia M, Knezevic D, Tovar C, et al. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7(11):1604-12
70. Marrelli M, Conforti F, Statti GA, et al. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin a-4. Curr Med Chem 2011;18(20):3035-81
71. Tron GC, Pirali T, Sorba G, et al. Medicinal chemistry of combretastatin A4: Present and future directions. J Med Chem 2006;49(11):3033-44
72. Simoni D, Grisolia G, Giannini G, et al. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem 2005;48(3):723-36
73. Leblanc R, Dickson J, Brown T, et al. Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorgan Med Chem 2005;13(21):6025-34
74. Bhat BA, Dhar KL, Puri SC, et al. Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg Med Chem Lett 2005;15(12):3177-80
75. Hu Y, Xue N, Yang X, et al. Indole substituted imidazoline-2-ketone derivative or its salt is useful for preparing anti-neoplastic drugs, is new. ZL200710071435; 2007
76. Hu Y, Xue N, Yang X, et al. New aryl substituted imidazoline-2-ketone derivative for preparing antitumor medicine. ZL200710071439; 2007
77. Baltimore D. Discovering NF-kappaB. Csh Perspect Biol 2009;1(1):a000026
78. Kwak J-H, Jung J-K, Lee H. Nuclear factor-kappa B inhibitors; a patent review (2006-2010). Expert Opin Ther Pat 2011;21(12):1897-910
79. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-55
80. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: A sensor for smoke and stress signals. Ann Ny Acad Sci 2005;1056:218-33
81. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006;25(51):6758-80
82. Breccia M, Alimena G. NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets 2010;14(11):1157-76
83. Tanaka K, Babic I, Nathanson D, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011;1(6):524-38
84. Mukogawa T, Koyama F, Tachibana M, et al. Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci 2003;94(8):745-50
85. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431-6
86. Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003; 289(1):27-35
87. Lin L, Ghosh S. A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 1996; 16(5):2248-54
88. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998;19(2):80-8
89. Baeuerle PA, Baltimore D, NF-kappa B. Ten years after. Cell 1996;87(1):13-20
90. Ahn KS, Aggarwal BB. Transcription factor NF-kappa B - A sensor for smoke and stress signals. 2005;1056:218-33
91. Olivier S, Close P, Castermans E, et al. Raloxifene-induced myeloma cell apoptosis: A study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 2006;69(5):1615-23
92. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/ NF-kappaB signal transduction pathway. Oncogene 1999;18(49):6896-909
93. Tepe JJ, Tepe J. Nuclear factor-kappa B inhibitors and uses thereof. WO2007133790; 2007
94. Hamby J, Tepe J. Substituted imidazoline compounds. WO2009048586; 2009
95. De Luca L. Naturally occurring and synthetic imidazoles: Their chemistry and their biological activities. Curr Med Chem 2006;13(1):1-23
96. Huang Z. New imidazoline, pyrrolidine containing compound for use in preparing pharmaceutical composition for treating and/or preventing infectious diseases. ZL200810128939; 2008